SCHEMBL10320157

SCHEMBL10320157

CC(C)(C)OC(=O)N1C[C@H]2CC(NCc3ccccc3)C[C@H]2C1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
JAK1 P23458 2/20 0.54
JAK2 O60674 1/20 0.54
NR1H2 P55055 1/20 0.51
STS P08842 1/20 0.47
NAMPT P43490 1/20 0.46
ACHE P22303 1/20 0.46
GPR119 Q8TDV5 2/20 0.45
TACR1 P25103 1/20 0.45
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45
USP30 Q70CQ3 2/20 0.44
LMNA P02545 1/20 0.44
KDM4E B2RXH2 1/20 0.44
PKM P14618 1/20 0.44
RORC P51449 1/20 0.43
KMT2A Q03164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4875893 1.00 JAK1 (0.54) JAK1JAK2NR1H2STSNAMPT
SCHEMBL22435955 1.00 JAK1 (0.54) JAK1JAK2NR1H2STSNAMPT
SCHEMBL10449417 1.00 JAK1 (0.54) JAK1JAK2NR1H2STSNAMPT
SCHEMBL6269523 0.94 JAK2 (0.50) JAK1JAK2NR1H2STSNAMPT
SCHEMBL10321076 0.92 JAK2 (0.66) JAK1JAK2STSACHEGPR119
SCHEMBL10450116 0.92 JAK2 (0.66) JAK1JAK2STSACHEGPR119
SCHEMBL9937172 0.90 STS (0.50) JAK1JAK2STSNAMPTACHE
SCHEMBL29577032 0.89 JAK2 (0.46) JAK1JAK2STSNAMPTACHE
SCHEMBL21276388 0.89 NR1H2 (0.50) JAK1JAK2NR1H2NAMPTGPR119
SCHEMBL8215310 0.87 CARM1 (0.47) JAK1JAK2NR1H2STSNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120184543-A1 DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184543-A1 DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF PLK2, PLK3, DMPK JAK1 904/4885JAK2 645/4885NR1H2 1812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.